Cornerstone Research worked with three experts to address class certification and damages issues. Retained by Morgan Lewis & Bockius Counsel for Cephalon Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., retained Cornerstone Research to analyze class certification and damages issues relating to the alleged off-label marketing of Actiq, a painkiller approved for the management of breakthrough cancer pain. A purported class of third-party payers (TPPs) claimed that Cephalon unjustly enriched itself by marketing Actiq for non-approved indications in order to increase prescription sales, and that they were damaged by Cephalon's actions. Cornerstone Research worked with three experts to address class certification and damages issues: Professor W. David Bradford of the University of Geo

Join for free to read